Mechanisms of resistance to aromatase inhibitors

Journal of Steroid Biochemistry and Molecular Biology

Volumn 95, Issue 1-5, 2005, Pages 167-172

  Dowsett, Mitch ^a   Martin, Lesley Ann ^a,b   Smith, Ian ^a   Johnston, Stephen ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Anastrozole; Aromatase inhibitor; Letrozole; Oestrogen receptor; Resistance

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; FORMESTANE; FULVESTRANT; GEFITINIB; GOSERELIN; LETROZOLE; TAMOXIFEN; UO 126;

BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; HUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENCE RISK; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 23744502200     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2005.04.022     Document Type: Conference Paper

References (25)

1. I.E. Smith, and M. Dowsett Aromatase inhibitors in breast cancer N. Engl. J. Med. 348 2003 2431 2442
2. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer an overview of the randomised trials Lancet 351 1998 1451 1467
3. M. Dowsett ATAC Trialists' Group Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status Breast Cancer Res. Treat. 82 Suppl. 1 2003 S7 (abstract 4)
4. M.J. Ellis, A. Coop, B. Singh, L. Mauriac, A. Llombert-Cussac, F. Janicke, W.R. Miller, D.B. Evans, M. Dugan, C. Brady, E. Quebe-Fehling, and M. Borgs Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J. Clin. Oncol. 19 2001 3808 3816
5. W. Eiermann, S. Paepke, J. Appfelstaedt, A. Llombart-Cussac, J. Eremin, J. Vinholes, L. Mauriac, M. Ellis, M. Lassus, H.A. Chaudri-Ross, M. Dugan, M. Borgs Letrozole Neo-Adjuvant Breast Cancer Study Group Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study Ann. Oncol. 12 2001 1527 1532
6. I.E. Smith, and M. Dowsett The Impact Trial. A multicentre double blind placebo controlled trial comparing neoadjuvant anastrozole with tamoxifen or the combination Breast Cancer Res. Treat. 82 Suppl. 1 2003 S6 (abstract 1)
7. M. Dowsett, I.E. Smith, S.R. Ebbs, J.M. Dixon, A. Skene, C. Griffith, I. Boeddinghaus, J. Salter, S. Detre, M. Hills, S. Ashley, S. Francis, G. Walsh, on behalf of IMPACT Trialists. Short-term changes in Ki67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival, Clin. Cancer Res. 11 (2005) 951s-958s.
8. A. Ring, and M. Dowsett Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications Clin. Breast Cancer 4 Suppl. 1 2003 S34 S41
9. E.V. Jensen, and E.R. de Sombre Steroid hormone binding and hormone receptors J.F. Holland E. Frei III R.C. Bast Jr. D.L. Kufe R.R. Morton R.R. Weichselbaum Cancer Medicine fourth ed. 1996 Williams and Wilkins Baltimore 1049 1060
10. M. Dowsett, J. Houghton, M. Baum, J. Salter, R. A'Hern, C. Iden, J. Farndon J. ER, PgR, c-erbB2 and EGFR in patients randomised to adjuvant tamoxifen: combinations of biomarkers as discriminants of treatment benefit, Ann. Oncol., in press.
11. P. Sourdaine, P. Mullen, R. White, J. Telford, M.G. Parker, and W.R. Miller Aromatase activity and CYP19 gene expression in breast cancers J. Steroid Biochem. Mol. Biol. 59 1996 191 198
12. B. Lloveras, R. Monzo, and A. Colomer Letrozole efficacy is related to human CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients Proc. Am. Soc. Clin. Oncol. 23 2004 4 (abstract 507)
13. A.M. Dunning, M. Dowsett, C.S. Healey, L. Tee, R.N. Luben, E. Folkerd, K.L. Novik, L. Kelemen, S. Ogata, P.D. Pharoah, D.F. Easton, N.E. Day, and B.A. Ponder Polymorphisms associated with circulating sex hormone levels in postmenopausal women J. Natl. Cancer Inst. 96 2004 936 945
14. S. Masamura, S.J. Santner, D.F. Heitjan, and R.J. Santen Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells J. Clin. Endocrinol. Metab. 80 1995 2918 2925
15. A.S. Coutts, and L.C. Murphy Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells Cancer Res. 58 1998 4071 4074
16. C.M.W. Chan, L.-A. Martin, S.R.D. Johnston, S. Ali, and M. Dowsett Molecular changes associated with acquisition of estrogen hypersensitivity in MCF-7 breast cancer cells on long-term estrogen deprivation J. Steroid Biochem. Mol. Biol. 81 2002 333 341
17. M. Dowsett, R.C. Stein, and R.C. Coombes Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients J. Steroid Biochem. Mol. Biol. 43 1992 155 159
18. M.-H. Jeng, M.A. Shupnik, T.P. Bender, E.H. Westin, D. Bandyopadhyay, R. Kumar, S. Masamura, and R.J. Santen Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells Endocrinology 139 1998 416 4174
19. L.-A. Martin, I. Farmer, S.R.D. Johnston, S. Ali, C. Marshall, and M. Dowsett Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation J. Biol. Chem. 278 2003 30458 30468
20. J. Font de Mora, and M. Brown AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor Mol. Cell Biol. 20 2000 5041 5047
21. S.L. Anzick, J. Kononen, R.L. Walker, D.O. Azorsa, M.M. Tanner, X.Y. Guan, G. Sauter, O.P. Kallioniemi, J.M. Trent, and P.S. Meltzer AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer Science (Washington, DC) 277 1997 965 968
22. H.J. List, R. Reiter, B. Singh, A. Wellstein, and A.T. Riegel Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue Breast Cancer Res. Treat. 68 2001 21 28
23. L.C. Murphy, S.L. Simon, A. Parkes, E. Leygue, H. Dotzlaw, L. Snell, S. Troup, A. Adeyinka, and P.H. Watson Altered expression of estrogen receptor coregulators during human breast tumorigenesis Cancer Res. 60 2000 6266 6271
24. W.S. Shim, M. Conaway, S. Masamura, W. Yue, J.P. Wang, R. Kmar, and R.J. Santen Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo Endocrinology 141 2000 396 405
25. A.U. Buzdar Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer Oncologist 8 2003 335 341